RE:RE:RE:RE:BioPub To further elaborate regarding the use of NMDA receptors inhibitors such as ifenprodil in cancer treatment, I found the following 2019 article from Sweden.
"Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning": by Beste Turanli et.al. https://www.workcast.com/ControlUsher.aspx?cpak=5155519046589836&pak=3511162085644479 The team reconstructed a prostate specific GEM which stands for Genome scale metabolic model (fear not, the article explains it). They examined 683 existing drugs which were initially paired down to 23 potential candidates for prostate cancer of which 12 had already been associated or tested for prostate cancer treatment. Out of the remaining 11 drugs previously not identified as anti-cancer agents, 8 showed a decrease in tumor growth. Lastly, after silico cell viability testing 4 were identified as novel candidates against prostate cancer. Ifenprofil showed the best effect by significantly reducing all 3 cancer cell lines. The article also states that other studies have found NMDA inhibitors drugs such as ifenprodil to have inhibitory effects on: esophageal,ovarian and pancratic cancers.